MedPath

Volatile Anesthetic Protection Of Renal transplants 1

Completed
Conditions
niertransplantatie
living donor kidney transplantation
Registration Number
NL-OMON38182
Lead Sponsor
niversitair Medisch Centrum Groningen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

donor/recipient couples requiring general anaesthesia for a living donor kidney donation/transplantation
age > 18 years

Exclusion Criteria

patient refusal
BMI< 17, >35
neurological disorder
recent use of psycho-active medication, including alcohol
Donor-recipient couples from the ABO-incompatible program
Altruistic donor

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary outcome measures:<br /><br>Signs of renal injury reflected by kidney injury biomarkers in transplanted<br /><br>kidney*s urine. We will use a set of biomarkers consisting of:<br /><br>1) KIM-1: Kidney Injury Molecule-1: a scavenger receptor on renal epithelial<br /><br>cells which converts the normal proximal tubule cell into a phagocyte. KIM-1<br /><br>expression is not measurable in normal proximal tubule cells and is markedly<br /><br>upregulated with injury/dedifferentiation. It is highly expressed on the apical<br /><br>domain of the cell and its large ectodomain is cleaved and is stable as it is<br /><br>excreted in the urine. Its presence in the urine is highly specific for kidney<br /><br>injury. No other organs have been shown to express KIM-1<br /><br>2) NAG: N-acetyl-glucosaminidase: lysosomal enzyme in proximal tubular<br /><br>epithelial cells, released during renal injury<br /><br>3) H-FABP: Heart-fatty-acid-binding-protein. Marker for distal tubular injury.</p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath